K. Moynihan

发表

Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy

Maxim N. Artyomov, D. Irvine, J. Kolls, 2016, Nature Communications.

Pharmacokinetic tuning of protein–antigen fusions enhances the immunogenicity of T-cell vaccines

D. Irvine, S. Bhatia, K. Wittrup, 2020, Nature Biomedical Engineering.

Radiation‐enhanced delivery of systemically administered amphiphilic‐CpG oligodeoxynucleotide

D. Irvine, S. Kron, K. Moynihan, 2017, Journal of controlled release : official journal of the Controlled Release Society.

Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity

Rebecca L. Holden, D. Irvine, Catherine J. Wu, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability

Rebecca L. Holden, D. Irvine, Mark R. Karver, 2018, Cancer Immunology Research.

Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy

D. Irvine, J. Tregoning, D. Barouch, 2018, The Journal of Immunology.

Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy.

Ryan L. Kelly, D. Irvine, K. Wittrup, 2016, Cell reports.

Temporally Programmed CD8α[superscrip +] DC Activation Enhances Combination Cancer Immunotherapy

Ryan L. Kelly, D. Irvine, K. Wittrup, 2016 .

Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells

D. Irvine, Chensu Wang, K. Rakhra, 2021, Science Immunology.

High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry

Prabhani U. Atukorale, D. Irvine, L. Tang, 2017, Nature Communications.

Structure-based programming of lymph-node targeting in molecular vaccines

Gregory L. Szeto, D. Irvine, Yiran Zheng, 2014, Nature.

Cell and fluid sampling microneedle patches for monitoring skin-resident immunity

Anasuya Mandal, Paula T. Hammond, J. Christopher Love, 2018, Science Translational Medicine.

Identification of Highly Cross-Reactive Mimotopes for a Public T Cell Response in Murine Melanoma

J. C. Love, D. Irvine, M. Birnbaum, 2022, bioRxiv.

Engineering immunity : enhancing T Cell vaccines and combination immunotherapies for the treatment of cancer

K. Moynihan, 2017 .

Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.

Gregory L. Szeto, D. Irvine, M. Hanson, 2015, The Journal of clinical investigation.

Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

D. Irvine, M. Yaffe, M. Mihm, 2015, Cancer cell.

Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding

D. Irvine, J. Kirkwood, E. Lipson, 2017, Science Immunology.

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

Ryan L. Kelly, D. Lauffenburger, D. Irvine, 2016, Nature Medicine.

Roles for Innate Immunity in Combination Immunotherapies.

Darrell J Irvine, D. Irvine, Kelly D Moynihan, 2017, Cancer research.

Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models

D. Irvine, K. Wittrup, K. Moynihan, 2019, Oncoimmunology.

Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles.

D. Irvine, Heikyung Suh, H. Ploegh, 2018, Biomaterials science.

Engineering New Approaches to Cancer Vaccines

D. Irvine, K. Moynihan, Naveen K. Mehta, 2015, Cancer Immunology Research.

Engineering New Approaches to Cancer Vaccines

D. Irvine, K. Moynihan, Naveen K. Mehta, 2015, Cancer Immunology Research.

Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice

D. Irvine, K. Wittrup, Murillo Silva, 2021, PloS one.

564 Single-cell transcriptomic analysis of immune compartments following combination immunotherapy treatment in poorly immunogenic tumors

Shuqiang Li, N. Hacohen, D. Irvine, 2021, Journal for ImmunoTherapy of Cancer.

Abstracts from the 4th ImmunoTherapy of Cancer Conference

R. Rees, F. Regnier, A. Trautmann, 2017, Journal of Immunotherapy for Cancer.

ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer

Z. Szallasi, D. Irvine, D. Keskin, 2023, Nature Cancer.

717 Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor efficacy and safety

T. Schumacher, Irene Ni, K. Moynihan, 2021, Journal for ImmunoTherapy of Cancer.

Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

D. Irvine, M. Yaffe, M. Mihm, 2015, Cancer cell.

Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability

Rebecca L. Holden, D. Irvine, Mark R. Karver, 2018, Cancer Immunology Research.